Aquestive Therapeutics, Inc.

AQST Healthcare Drug Manufacturers Specialty & Generic

Aquestive Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.5 million, down 22.6% from fiscal 2024. In the quarter to June 2026, revenue grew 38.2%, EPS fell 28.6%, free cash flow fell 20.4% and total debt rose 59.1%, each against the same quarter a year earlier.

3.78 0.28 −6.90%
Market cap
$509.6M
P/E
0.0×
Fwd P/E
−9.7×
Dividend yield
—
F-score
2/9
Altman Z
−2.19
Beneish M
−1.91
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Total current assets
149.27 88.22 40.97 39.89 47.26 44.63 68.31 74.20 28.16 23.33
Total non-current assets
11.16 13.20 16.45 17.18 14.73 18.26 10.17 12.65 14.95 —
Total Assets
160.43 101.42 57.42 57.07 61.99 62.88 78.48 86.85 43.12 39.39
Total current liabilities
47.61 18.87 18.31 39.53 21.96 21.10 18.56 32.95 15.35 10.81
Total non-current liabilities
146.48 142.72 145.60 136.10 122.16 90.28 66.05 43.82 54.26 —
Total liabilities
194.09 161.58 163.91 175.62 144.13 111.38 84.60 76.77 69.61 56.97
Common Equity (Total)
(33.66) (60.16) (106.49) (118.55) (82.13) (48.50) (6.12) 10.08 (107.37) (95.97)
Shareholders Equity (Total)
(33.66) (60.16) (106.49) (118.55) (82.13) (48.50) (6.12) 10.08 (26.49) (17.58)
Total Debt
27.52 32.50 27.51 33.45 51.55 34.33 60.34 42.60 45.51 38.65

Show all line items

In millions of $ except per-share values · columns are period end dates